Literature DB >> 25102986

Fusobacterium detected in colonic biopsy and clinicopathological features of ulcerative colitis in Japan.

Tomomitsu Tahara1, Tomoyuki Shibata, Tomohiko Kawamura, Masaaki Okubo, Yuichiro Ichikawa, Kazuya Sumi, Masahiro Miyata, Takamitsu Ishizuka, Masakatsu Nakamura, Mitsuo Nagasaka, Yoshihito Nakagawa, Naoki Ohmiya, Tomiyasu Arisawa, Ichiro Hirata.   

Abstract

BACKGROUND AND AIMS: Fusobacterium species are part of the gut microbiome in humans, but some species have been recognized as opportunistic pathogens implicated in inflammatory diseases including inflammatory bowel diseases. Here, we performed prevalence screening of Fusobacterium in ulcerative colitis (UC) in Japanese patients.
METHODS: We examined Fusobacterium nucleatum (F. nucleatum) and whole Fusobacterium species (Pan-fusobacterium) by quantitative real-time PCR in 163 inflamed mucosae from 152 UC patients. Data were correlated with clinical subtypes of UC.
RESULTS: In an initial prevalence screen, F. nucleatum and Pan-fusobacterium were detected in 6.3 % (4/64) and 53.1 % (34/64). For all 163 mucosae, the prevalence of Pan-fusobacterium was 54.6 % (89/163). Pan-fusobacterium status was concordant in inflamed and normal adjacent samples, and the matched cases during 1-year follow-up colonoscopy. The higher amount of Pan-fusobacterium was observed in chronic continuous type compared to one attack and relapse/remitting type (p = 0.039). The higher amount of Pan-fusobacterium was also associated with rather mild clinical course of disease, such as non-steroid dependency (p = 0.015), non-refractory phenotype (p = 0.013), and non-severe phenotype (p = 0.04). Based on the distribution of Pan-fusobacterium measurable cases, we identified 10 cases as having a high amount of Pan-fusobacterium (FB-high). The clinicopathological features of FB-high UC cases were also highlighted by chronic continuous type and mild phenotypes of disease.
CONCLUSION: Whole Fusobacterium species, but not F. nucleatum, are common in UC patients and have a role in persistence of colonic inflammation in UC. However, Fusobacterium infection is associated with rather mild clinical phenotypes of UC.

Entities:  

Mesh:

Year:  2014        PMID: 25102986     DOI: 10.1007/s10620-014-3316-y

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  21 in total

Review 1.  [Etiopathogenesis of inflammatory bowel diseases].

Authors:  László Lakatos; Péter László Lakatos
Journal:  Orv Hetil       Date:  2003-09-21       Impact factor: 0.540

2.  Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host.

Authors:  Jaclyn Strauss; Gilaad G Kaplan; Paul L Beck; Kevin Rioux; Remo Panaccione; Rebekah Devinney; Tarah Lynch; Emma Allen-Vercoe
Journal:  Inflamm Bowel Dis       Date:  2011-01-13       Impact factor: 5.325

Review 3.  Microbial influences in inflammatory bowel diseases.

Authors:  R Balfour Sartor
Journal:  Gastroenterology       Date:  2008-02       Impact factor: 22.682

4.  Association between functional promoter polymorphisms of macrophage migration inhibitory factor (MIF) gene and ulcerative colitis in Japan.

Authors:  Hisakazu Shiroeda; Tomomitsu Tahara; Masakatsu Nakamura; Tomoyuki Shibata; Tomoe Nomura; Hideto Yamada; Ranji Hayashi; Takashi Saito; Masayoshi Yamada; Tomoki Fukuyama; Toshimi Otsuka; Hirokazu Yano; Kazuaki Ozaki; Mutsumi Tsuchishima; Mikihiro Tsutsumi; Tomiyasu Arisawa
Journal:  Cytokine       Date:  2010-08       Impact factor: 3.861

5.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis.

Authors:  J A Eaden; K R Abrams; J F Mayberry
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

6.  Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis.

Authors:  T Ohkusa; I Okayasu; T Ogihara; K Morita; M Ogawa; N Sato
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

Review 7.  Fusobacterium nucleatum in periodontal health and disease.

Authors:  Benoit Signat; Christine Roques; Pierre Poulet; Danielle Duffaut
Journal:  Curr Issues Mol Biol       Date:  2011-01-10       Impact factor: 2.081

8.  Phylogenetic analysis of dysbiosis in ulcerative colitis during remission.

Authors:  Mirjana Rajilić-Stojanović; Fergus Shanahan; Francisco Guarner; Willem M de Vos
Journal:  Inflamm Bowel Dis       Date:  2013-03       Impact factor: 5.325

9.  Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease.

Authors:  A Darfeuille-Michaud; C Neut; N Barnich; E Lederman; P Di Martino; P Desreumaux; L Gambiez; B Joly; A Cortot; J F Colombel
Journal:  Gastroenterology       Date:  1998-12       Impact factor: 22.682

10.  Influence of IL17A polymorphisms (rs2275913 and rs3748067) on the susceptibility to ulcerative colitis.

Authors:  Ranji Hayashi; Tomomitsu Tahara; Hisakazu Shiroeda; Takashi Saito; Masakatsu Nakamura; Mikihiro Tsutsumi; Tomoyuki Shibata; Tomiyasu Arisawa
Journal:  Clin Exp Med       Date:  2012-09-07       Impact factor: 3.984

View more
  20 in total

1.  Fusobacterium varium in ulcerative colitis: is it population-based?

Authors:  Emma Allen-Vercoe
Journal:  Dig Dis Sci       Date:  2014-10-14       Impact factor: 3.199

2.  Microbial characterization of esophageal squamous cell carcinoma and gastric cardia adenocarcinoma from a high-risk region of China.

Authors:  Dantong Shao; Emily Vogtmann; Anqi Liu; Junjie Qin; Wen Chen; Christian C Abnet; Wenqiang Wei
Journal:  Cancer       Date:  2019-07-29       Impact factor: 6.860

Review 3.  Fusobacterium nucleatum: a commensal-turned pathogen.

Authors:  Yiping W Han
Journal:  Curr Opin Microbiol       Date:  2015-01-08       Impact factor: 7.934

4.  Fusobacterium nucleatum promotes the progression of colorectal cancer by interacting with E-cadherin.

Authors:  Chun-Ting Ma; He-Sheng Luo; Feng Gao; Qin-Cai Tang; Wei Chen
Journal:  Oncol Lett       Date:  2018-06-11       Impact factor: 2.967

Review 5.  New Insights into the Role of Oral Microbiota Dysbiosis in the Pathogenesis of Inflammatory Bowel Disease.

Authors:  Ying Qi; Hui-Min Wu; Zhao Yang; Yi-Fei Zhou; Lei Jin; Miao-Fang Yang; Fang-Yu Wang
Journal:  Dig Dis Sci       Date:  2021-02-01       Impact factor: 3.199

6.  Exposure to environmental microbiota explains persistent abdominal pain and irritable bowel syndrome after a major flood.

Authors:  NurFadhilah Yusof; Nurhazwani Hamid; Zheng Feei Ma; Rona Marie Lawenko; Wan Mohd Zahiruddin Wan Mohammad; Deirdre A Collins; Min Tze Liong; Toshitaka Odamaki; Jinzhong Xiao; Yeong Yeh Lee
Journal:  Gut Pathog       Date:  2017-12-14       Impact factor: 4.181

Review 7.  Influence of Microbiota on Intestinal Immune System in Ulcerative Colitis and Its Intervention.

Authors:  Sai-Long Zhang; Shu-Na Wang; Chao-Yu Miao
Journal:  Front Immunol       Date:  2017-11-28       Impact factor: 7.561

8.  Fusobacterium Isolates Recovered From Colonic Biopsies of Inflammatory Bowel Disease Patients in Korea.

Authors:  Yangsoon Lee; Chang Soo Eun; A Reum Lee; Chan Hyuk Park; Dong Soo Han
Journal:  Ann Lab Med       Date:  2016-07       Impact factor: 3.464

9.  Potential link between Fusobacterium enrichment and DNA methylation accumulation in the inflammatory colonic mucosa in ulcerative colitis.

Authors:  Tomomitsu Tahara; Ichiro Hirata; Naoko Nakano; Sayumi Tahara; Noriyuki Horiguchi; Tomohiko Kawamura; Masaaki Okubo; Takamitsu Ishizuka; Hyuga Yamada; Dai Yoshida; Takafumi Ohmori; Kohei Maeda; Naruomi Komura; Hirokazu Ikuno; Yasutaka Jodai; Toshiaki Kamano; Mitsuo Nagasaka; Yoshihito Nakagawa; Tetsuya Tuskamoto; Makoto Urano; Tomoyuki Shibata; Makoto Kuroda; Naoki Ohmiya
Journal:  Oncotarget       Date:  2017-06-27

10.  Fusobacterium nucleatum in gastroenterological cancer: Evaluation of measurement methods using quantitative polymerase chain reaction and a literature review.

Authors:  Kensuke Yamamura; Yoshifumi Baba; Keisuke Miyake; Kenichi Nakamura; Hironobu Shigaki; Kosuke Mima; Junji Kurashige; Takatsugu Ishimoto; Masaaki Iwatsuki; Yasuo Sakamoto; Yoichi Yamashita; Naoya Yoshida; Masayuki Watanabe; Hideo Baba
Journal:  Oncol Lett       Date:  2017-09-19       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.